WHWK supply chain intelligence for Whitehawk Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Whitehawk Therapeutics, Inc. (WHWK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CITIZENS-JMP-SECURITIES-LLC | CITIZENS-JMP-SECURITIES-LLC | 92% | Jefferies LLC, Leerink Partners LLC, Oppenheimer & Co. Inc., Citizens JMP Securities, LLC, and JonesTrading Institutional Services LLC acted as placement agents for the PIPE Financing and the Company… |
| JEFFERIES-LLC | JEFFERIES-LLC | 92% | Jefferies LLC, Leerink Partners LLC, Oppenheimer & Co. Inc., Citizens JMP Securities, LLC, and JonesTrading Institutional Services LLC acted as placement agents for the PIPE Financing and the Company… |
| JONESTRADING-INSTITUTIONAL-SERVICES-LLC | JONESTRADING-INSTITUTIONAL-SERVICES-LLC | 92% | Jefferies LLC, Leerink Partners LLC, Oppenheimer & Co. Inc., Citizens JMP Securities, LLC, and JonesTrading Institutional Services LLC acted as placement agents for the PIPE Financing and the Company… |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 92% | Jefferies LLC, Leerink Partners LLC, Oppenheimer & Co. Inc., Citizens JMP Securities, LLC, and JonesTrading Institutional Services LLC acted as placement agents for the PIPE Financing and the Company… |
| OPPENHEIMER-CO-INC | OPPENHEIMER-CO-INC | 92% | Jefferies LLC, Leerink Partners LLC, Oppenheimer & Co. Inc., Citizens JMP Securities, LLC, and JonesTrading Institutional Services LLC acted as placement agents for the PIPE Financing and the Company… |
| BMY | Bristol-Myers Squibb Company | 90% | Reciprocal relationship from BMY graph: Reciprocal relationship from WHWK graph: Reciprocal relationship from BMY graph: Reciprocal relationship from WHWK graph: Under the terms of the BMS License Ag… |
| BMY | Bristol-Myers Squibb Company | 90% | Under the terms of the BMS License Agreement, BMS agreed to supply the Company with licensed products of FYARRO necessary for clinical or non-clinical development. |
| HANGZHOU-DAC | HANGZHOU-DAC | 90% | Initially, we intend to continue to benefit from the continuity of partnership with WuXi Biologics and Hangzhou DAC for ADC manufacturing. |
| WUXI-BIOLOGICS | WUXI-BIOLOGICS | 90% | Initially, we intend to continue to benefit from the continuity of partnership with WuXi Biologics and Hangzhou DAC for ADC manufacturing. |
| WUXI-BIOLOGICS-SHANGHAI-FX-CO-LTD | WUXI-BIOLOGICS-SHANGHAI-FX-CO-LTD | 80% | Under the License Agreement, the Company paid WuXi Biologics a non-refundable, partial upfront payment of $ 6.0 million on December 20, 2024. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from WHWK graph: . For the periods presented and through the FYARRO Divestiture (as defined below), our lead drug product was FYARRO ® … |
| BMY | Bristol-Myers Squibb Company | 72% | . For the periods presented and through the FYARRO Divestiture (as defined below), our lead drug product was FYARRO ® (sirolimus protein-bound particles for injectable suspension (albumin-bound); nab… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from WHWK graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from WHWK graph: Reciprocal relationship from BMYM… |
| BMYMP | Bristol-Myers Squibb Co | 72% | . For the periods presented and through the FYARRO Divestiture (as defined below), our lead drug product was FYARRO ® (sirolimus protein-bound particles for injectable suspension (albumin-bound); nab… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from WHWK graph: e foreign regulations; • challenges enforcing our contractual and intellectual property rights, especially in those … |
| SNYNF | Sanofi | 72% | e foreign regulations; • challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to t… |
| AADI-BIOSCIENCE-INC | AADI-BIOSCIENCE-INC | 62% | ofessionals (such as physician assistants and nurse 37 Table of Contents practitioners, among others), and teaching hospitals, and information regarding ownership and investment interests held by phy… |
| AADI-SUBSIDIARY-INC | AADI-SUBSIDIARY-INC | 62% | ofessionals (such as physician assistants and nurse 37 Table of Contents practitioners, among others), and teaching hospitals, and information regarding ownership and investment interests held by phy… |
| ABRAXIS-BIOSCIENCE-LLC | ABRAXIS-BIOSCIENCE-LLC | 62% | . For the periods presented and through the FYARRO Divestiture (as defined below), our lead drug product was FYARRO ® (sirolimus protein-bound particles for injectable suspension (albumin-bound); nab… |
| AERPIO-PHARMACEUTICALS-INC | AERPIO-PHARMACEUTICALS-INC | 62% | ofessionals (such as physician assistants and nurse 37 Table of Contents practitioners, among others), and teaching hospitals, and information regarding ownership and investment interests held by phy… |
| COMPANY-LLC | COMPANY-LLC | 62% | patent costs, facility costs and travel costs. 122 Table of Contents Research and Development Expenses Research and development expenses, which consist primarily of costs associated with our product … |
| IN-CATALYST-PHARMS-INC | IN-CATALYST-PHARMS-INC | 62% | cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct … |
| SI | Shoulder Innovations, Inc. | 62% | Reciprocal relationship from SI graph: Reciprocal relationship from WHWK graph: Reciprocal relationship from SI graph: Reciprocal relationship from WHWK graph: Reciprocal relationship from SI graph: … |
| ZETA-ACQUISITION-CORP | ZETA-ACQUISITION-CORP | 62% | ofessionals (such as physician assistants and nurse 37 Table of Contents practitioners, among others), and teaching hospitals, and information regarding ownership and investment interests held by phy… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| WHWK-DEBT-13566 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-12-31. |
| WHWK-DEBT-13565 | Warrants outstanding: 317562 | 90% | xbrl warrant detail from xbrl 2023-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| WHWK-OWNER-ACUTA-CAPITAL-PARTNERS-LLC | Acuta Capital Partners LLC | 95% | 13F/ownership overlay lists Acuta Capital Partners LLC; shares held 3,410,402; ownership 6.90%; value $13.4M; as of 2025-12-31. |
| WHWK-OWNER-STEMPOINT-CAPITAL-LP | Stempoint Capital LP | 95% | 13F/ownership overlay lists Stempoint Capital LP ; shares held 1,458,807; ownership 2.95%; value $5.7M; as of 2025-12-31. |
| WHWK-OWNER-SUVRETTA-CAPITAL-MANAGEMENT-LLC | Suvretta Capital Management, LLC | 95% | 13F/ownership overlay lists Suvretta Capital Management, LLC; shares held 3,700,000; ownership 7.48%; value $14.5M; as of 2025-12-31. |
| WHWK-OWNER-QVT-FINANCIAL-LP | QVT Financial LP | 95% | 13F/ownership overlay lists QVT Financial LP; shares held 4,615,709; ownership 9.33%; value $18.1M; as of 2025-12-31. |
| WHWK-OWNER-AVORO-CAPITAL-ADVISORS-LLC | Avoro Capital Advisors LLC | 95% | 13F/ownership overlay lists Avoro Capital Advisors LLC; shares held 2,849,402; ownership 5.76%; value $11.2M; as of 2025-12-31. |
| WHWK-OWNER-YU-FAN | Yu Fan | 95% | 13F/ownership overlay lists Yu Fan; shares held 2,070,000; ownership 4.19%; value $8.1M; as of 2025-12-31. |
| WHWK-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | Vanguard Capital Management LLC | 95% | 13F/ownership overlay lists Vanguard Capital Management LLC; shares held 1,315,770; ownership 2.66%; value $5.2M; as of 2026-03-31. |
| WHWK-OWNER-KVP-CAPITAL-ADVISORS-LP | Kvp Capital Advisors, LP | 95% | 13F/ownership overlay lists Kvp Capital Advisors, LP; shares held 2,165,997; ownership 4.38%; value $8.5M; as of 2025-12-31. |
| WHWK-OWNER-ORBIMED-ADVISORS-LLC | Orbimed Advisors LLC. | 95% | 13F/ownership overlay lists Orbimed Advisors LLC.; shares held 4,166,000; ownership 8.42%; value $16.3M; as of 2025-12-31. |
| WHWK-OWNER-SIREN-L-L-C | Siren, L.L.C. | 95% | 13F/ownership overlay lists Siren, L.L.C.; shares held 2,082,000; ownership 4.21%; value $8.2M; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 |